SOHO 2024 | A trial investigating the addition of blinatumomab to consolidation chemotherapy in Ph- ALL
Mark Litzow, MD, Mayo Clinic, Rochester, MN, discusses a large U.S. trial in which patients with Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL) underwent induction chemotherapy, followed by randomization to consolidation chemotherapy with or without the addition of blinatumomab. The study demonstrated a statistically significant improvement in 3-year overall survival (OS) for patients receiving blinatumomab, especially in those aged 30-55 and in favorable or unfavorable risk groups. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
